Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon19 and exon 21 mutations treated with gefitinib or erlotinibRIELY, Gregory J; PAO, William; PHAM, Duykhanh et al.Clinical cancer research. 2006, Vol 12, Num 3, pp 839-844, issn 1078-0432, 6 p., 1Article

Molecular Characteristics of Bronchioloalveolar Carcinoma and Adenocarcinoma, Bronchioloalveolar Carcinoma Subtype, Predict Response to ErlotinibMILLER, Vincent A; RIELY, Gregory J; HERBST, Roy S et al.Journal of clinical oncology. 2008, Vol 26, Num 9, pp 1472-1478, issn 0732-183X, 7 p.Article

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor : Mutant lung adenocarcinomas with acquired resistance to kinase inhibitorsBALAK, Marissa N; YIXUAN GONG; LADANYI, Marc et al.Clinical cancer research. 2006, Vol 12, Num 21, pp 6494-6501, issn 1078-0432, 8 p.Article